During the past decade, Southern New Hampshire Diabetes and Endocrinology conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 11 clinical trials were completed, i.e. on average, 78.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 9 clinical trials were completed. i.e. 180% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Southern New Hampshire Diabetes and Endocrinology" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Boehringer Ingelheim" with 1 trials sponsored, "Kowa Research Institute, Inc." with 1 trials sponsored, "Mylan Inc." with 1 trials sponsored and "OPKO Health, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Southern New Hampshire Diabetes and Endocrinology" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Insulet Corporation" with 1 trials as a collaborator and "Mylan GmbH" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Southern New Hampshire Diabetes and Endocrinology" are "Type 2 Diabetes Mellitus" (4 trials), "Type 1 Diabetes Mellitus" (3 trials), "Diabetes Mellitus, Type 1" (2 trials), "Diabetes Mellitus, Type 2" (2 trials) and "Type 2 Diabetes" (2 trials). Many other conditions were trialed in "Southern New Hampshire Diabetes and Endocrinology" in a lesser frequency.

Most popular intervention types in "Southern New Hampshire Diabetes and Endocrinology" are "Drug" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Tirzepatide" (4 trials), "Insulin Degludec" (3 trials), "Insulin Glargine" (3 trials) and "Insulin Lispro" (2 trials). Other intervention names were less common.

The vast majority of trials in "Southern New Hampshire Diabetes and Endocrinology" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Southern New Hampshire Diabetes and Endocrinology". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Southern New Hampshire Diabetes and Endocrinology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Southern New Hampshire Diabetes and Endocrinology, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".